Patents by Inventor Kirsten Timms
Kirsten Timms has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230212653Abstract: Provided herein are methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: December 6, 2022Publication date: July 6, 2023Applicant: Myriad Genetics, Inc.Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20230117133Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: December 14, 2022Publication date: April 20, 2023Applicant: Myriad Genetics, Inc.Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
-
Publication number: 20230111438Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: December 14, 2022Publication date: April 13, 2023Applicant: Myriad Genetics, Inc.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20220205022Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.Type: ApplicationFiled: December 8, 2021Publication date: June 30, 2022Applicant: Myriad Genetics, Inc.Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20220205046Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: October 12, 2021Publication date: June 30, 2022Applicant: Myriad Genetics, Inc.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Patent number: 11225685Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.Type: GrantFiled: March 11, 2020Date of Patent: January 18, 2022Assignee: MYRIAD GENETICS, INC.Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Patent number: 11174519Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: GrantFiled: November 21, 2019Date of Patent: November 16, 2021Assignee: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20210348240Abstract: The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.Type: ApplicationFiled: July 22, 2021Publication date: November 11, 2021Applicant: Myriad Genetics, Inc.Inventors: Kirsten Timms, Brian Allen, Anne-Renee Hartman
-
Publication number: 20210310079Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: June 21, 2021Publication date: October 7, 2021Applicant: Myriad Genetics, Inc.Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin
-
Patent number: 11104956Abstract: The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.Type: GrantFiled: December 5, 2014Date of Patent: August 31, 2021Assignee: Myriad Genetics, Inc.Inventors: Kirsten Timms, Brian Allen, Anne-Renee Hartman
-
Publication number: 20210262016Abstract: This invention provides methods and compositions for detecting somatic mutations in cancer cells. The methods can be used for measuring tumor mutation burden. Provided are methods for identifying and treating subjects who benefit from treatment with anticancer agents such as immune checkpoint inhibitors, methods for treating cancer in a subject, and methods for monitoring and prognosing a subject having cancer.Type: ApplicationFiled: May 6, 2021Publication date: August 26, 2021Applicant: MYRIAD GENETICS, INC.Inventors: Andrey ZHARKIKH, Kirsten TIMMS, Michael PERRY, Alexander GUTIN
-
Publication number: 20200399713Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Applicant: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Patent number: 10851425Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: GrantFiled: September 19, 2019Date of Patent: December 1, 2020Assignee: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20200239943Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.Type: ApplicationFiled: March 11, 2020Publication date: July 30, 2020Applicant: MYRIAD GENETICS, INC.Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20200190602Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: February 24, 2020Publication date: June 18, 2020Applicant: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Patent number: 10626449Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.Type: GrantFiled: January 23, 2017Date of Patent: April 21, 2020Assignee: MYRIAD GENETICS, INC.Inventors: Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Patent number: 10612098Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: GrantFiled: June 24, 2016Date of Patent: April 7, 2020Assignee: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20200087737Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: November 21, 2019Publication date: March 19, 2020Applicant: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Publication number: 20200010913Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: ApplicationFiled: September 19, 2019Publication date: January 9, 2020Applicant: MYRIAD GENETICS, INC.Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
-
Patent number: 10400287Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.Type: GrantFiled: February 15, 2017Date of Patent: September 3, 2019Assignee: Myriad Genetics, Inc.Inventors: Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid